Brean Lifts PT on Inovio Pharma (INO) to $5; Expects Strong Data from VGX-3100 Phase 2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Inovio Pharmaceuticals (INO) Price Target Lifted to $6 at Maxim Group
March 18, 2014 7:12 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals (NYSE: INO) and doubled his price target from $3 to $6 following fourth quarter results, saying the best is still ahead.
Kolbert notes the company has plenty of capital runway for... More
Inovio Pharma (INO) Posts Q4 Loss of 4c/Share; Offers Corp. Update
March 17, 2014 6:06 AM EDTInovio Pharmaceuticals, Inc. (AMEX: INO) reported Q4 EPS of ($0.04), $0.01 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.36 million.
orporate Update
Corporate Development
In a major corporate development for the Company, Roche and Inovio entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA vaccine products targeting prostate cancer and hepatitis B. Roche licensed Inovio's therapeutic vaccines INO-5150 for prostate cancer and INO-1800 for hepatitis B as well as the use of Inovio's CELLECTRA®... More
